A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
about
Clinical development of Ebola vaccinesDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsMeasuring Cellular Immunity to Influenza: Methods of Detection, Applications and ChallengesHIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physiciansConsensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cellsLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Adenoviral vectors as novel vaccines for influenza.Novel directions in HIV-1 vaccines revealed from clinical trialsNonreplicating vectors in HIV vaccines.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.The influence of delivery vectors on HIV vaccine efficacyFirst-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.Novel vaccine vectors for HIV-1.Broad HIV epitope specificity and viral inhibition induced by multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsHeterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsThe F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.Development of prophylactic vaccines against HIV-1.Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensA Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.Novel HIV vaccine strategies: overview and perspective.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses.Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.Adenoviral vector-based strategies against infectious disease and cancer.Novel viral vectors in infectious diseases.Clade A HIV-1 Gag-specific T cell responses are frequent but do not correlate with viral loads in a cohort of treatment-naive HIV-infected individuals living in Guinea-Bissau.Progress in HIV vaccine development
P2860
Q26775792-71EDBB22-E68D-4838-983E-E59330D41FEDQ26782083-70D2323B-61CE-45CA-B547-B50177EB67E2Q26783884-6D23F1AA-A892-4749-BE4F-793575284033Q28082836-9788A5BA-17E6-48E9-80A4-A21F38966B75Q28487823-AE55B566-6A9D-431C-A4C1-69717E3962C9Q28654629-EA32F250-74D0-4E86-BB92-4839A0438709Q30364312-74914D4F-DF08-4E8B-9ED3-429A8C490470Q30370445-B040A641-DE1D-42F7-9748-96093CB8F5CAQ33645528-5599358F-4541-4D68-B84B-33F8D6106EC4Q33693891-4ABA7F2E-25FA-4350-B736-6C14E6D26DB1Q33875160-1CDE4266-444D-4E2D-AD5D-73EDA82E2A85Q34077543-D9180C43-CFA3-4F1C-BE97-3376F8936162Q34209026-4E85C3DC-42FD-4C64-B844-4FC03A773701Q34232909-D5BE3A97-7597-4559-8897-8AE5B630A242Q34541191-D8FABE81-2FB7-4123-BC1D-7DCA07423EDBQ35114907-76B31C76-FBA4-47E9-9A63-116C09DC59A0Q35344875-1B208246-7295-4EAE-AE1F-1E1D2EB38CD0Q35593139-C01D4C57-6E41-48BA-B1CE-671E3F8E7324Q35739841-CF7D635B-184F-470D-92E2-93F919A91924Q36192765-68FDD850-0977-42A6-B75D-10CAB72F3A87Q36288468-498301B7-9CA2-4DCD-902A-99ABCECB93CCQ36580911-AFE5CC5A-1041-4387-BDB3-CAD9D38F74DBQ37042563-F5A03E32-57E4-4EFE-81A7-D19A98505226Q37277825-1AF4022F-C385-48E3-91A0-E531FC9C71EEQ37578465-8AD093BB-E090-4EA3-84BD-35B3C598B9B0Q37656908-969333EF-3368-4A5E-B2B4-824BFEE2EB9CQ37668399-0BFF5F5E-A8F1-44E7-8A82-55AE779394CCQ38096489-F2223924-1D06-4037-ABDC-87E77FBD27BAQ38096490-50773A0D-8C3E-411A-B497-F39E078CFDF5Q38184579-F79CE16C-7F78-4E08-A04C-188466354199Q38284700-623F6ADF-CE17-497F-9F46-D96632A7138BQ38619108-0537AEEE-A39D-43FC-B775-8F4518468E68Q38712002-846AC814-AF46-4E56-97B6-65560837875CQ38748193-CC34EC77-9E06-489E-929F-170A4B040FB1Q38758212-F900A099-895B-403A-A8D8-4A4DAD01E19FQ38814885-03B18B63-9842-43FD-84F6-2F3AA64CE08EQ40059020-C7AF42AC-BF5B-492D-8101-86E00191211FQ42529284-31BA3099-D15A-48ED-B606-39116E6ED872Q56970600-927E9A9A-4732-4C33-B9FD-72B805B118D6
P2860
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase I double blind, placeb ...... in healthy uninfected adults.
@ast
A phase I double blind, placeb ...... in healthy uninfected adults.
@en
A phase I double blind, placeb ...... in healthy uninfected adults.
@nl
type
label
A phase I double blind, placeb ...... in healthy uninfected adults.
@ast
A phase I double blind, placeb ...... in healthy uninfected adults.
@en
A phase I double blind, placeb ...... in healthy uninfected adults.
@nl
prefLabel
A phase I double blind, placeb ...... in healthy uninfected adults.
@ast
A phase I double blind, placeb ...... in healthy uninfected adults.
@en
A phase I double blind, placeb ...... in healthy uninfected adults.
@nl
P2093
P2860
P50
P1433
P1476
A phase I double blind, placeb ...... in healthy uninfected adults.
@en
P2093
Burc Barin
Catherine A Bunce
Christine M Hay
Devika Zachariah
Dilbinder Gill
Eddy Sayeed
Emmanuel Cormier
Hannah Cheeseman
Jakub Kopycinski
James Ackland
P2860
P304
P356
10.1371/JOURNAL.PONE.0041936
P407
P577
2012-08-03T00:00:00Z